Corvus Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Corvus Pharmaceuticals, Inc. (CRVS) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $18.18 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-04
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $18.18M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $8.88M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $7.92M, a 46.79% increase year-over-year.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$605.00K.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$42.56M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$92.03M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $18.18M 10-Q · filed 2017-05-04 | $27.05M derived: sum of 2 quarters · filed 2017-05-04 | $34.97M derived: sum of 3 quarters · filed 2017-05-04 | $34.37M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $16.80M derived: sum of 2 quarters · filed 2017-03-10 | $16.19M derived: sum of 3 quarters · filed 2017-03-10 | -$42.56M 10-K · filed 2017-03-10 |
| 2016-09-30 | $7.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $7.31M derived: sum of 2 quarters · filed 2016-11-03 | -$51.43M 10-Q · filed 2016-11-03 | -$122.26M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-06-30 | -$605.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$59.35M 10-Q · filed 2016-08-04 | -$130.18M derived: sum of 3 quarters · filed 2017-05-04 | -$124.78M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-03-31 | -$58.75M 10-Q · filed 2017-05-04 | -$129.57M derived: sum of 2 quarters · filed 2017-05-04 | -$124.18M derived: sum of 3 quarters · filed 2017-05-04 | -$150.46M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | -$70.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$65.43M derived: sum of 2 quarters · filed 2017-03-10 | -$91.71M derived: sum of 3 quarters · filed 2017-03-10 | -$92.03M 10-K · filed 2017-03-10 |
| 2015-09-30 | $5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$20.88M derived: sum of 2 quarters · filed 2016-11-03 | -$21.20M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | -$26.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$26.60M 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | -$324.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |